secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001178913-25-002008
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic
--------------------------------------------------------------------------------

- SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.
- Dose-dependent reduction observed in Panc-1 (pancreatic), A427 (lung) cell lines at nanomolar concentrations.
- Company to conduct additional lung (NSCLC) cancer cell line study in coming weeks.
- KRAS G12D mutation targeted; addresses pancreatic (~90%), colorectal (~45%), and lung (~35%) cancers.
- Ilan Hadar cites SIL204's enhanced lipid-conjugate delivery enabling potent activity at low doses.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002008/0001178913-25-002008-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002008/zk2533298.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002008

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer